ReviewPLoS pathogens2015
Ebolavirus Evolution: Past and Present.
Review in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A novelMicrobiology spectrum · 2023Article
- Article
- Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response.Pathogens (Basel, Switzerland) · 2021Review
- Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.Frontiers in immunology · 2020Review
- Article
- Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: A preliminary report.PLoS neglected tropical diseases · 2019Article
- An exploration of conditions proposed to trigger the Ebola virus glycoprotein for fusion.PloS one · 2019Article
- Stochastic dynamics of an epidemic with recurrent spillovers from an endemic reservoir.Journal of theoretical biology · 2018Article
- Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.The Journal of biological chemistry · 2018Article
- Transmission, Human Population, and Pathogenicity: the Ebola Case in Point.Microbiology spectrum · 2018Review
- Different effects of two mutations on the infectivity of Ebola virus glycoprotein in nine mammalian species.The Journal of general virology · 2018Article
- Predicting Interactions between Virus and Host Proteins Using Repeat Patterns and Composition of Amino Acids.Journal of healthcare engineering · 2018Article
- Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody.Immunology letters · 2017Article
- Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Article
- Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.Science translational medicine · 2017Article
- The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.PLoS neglected tropical diseases · 2017Article
- Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.Advances in virus research · 2017Review
- Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The past year has marked the most devastating Ebola outbreak the world has ever witnessed, with over 28,000 cases and over 11,000 deaths. Ebola virus (EBOV) has now been around for almost 50 years. In this review, we discuss past and present outbreaks of EBOV and how those variants evolved over time. We explore and discuss selective pressures that drive the evolution of different Ebola variants, and how they may modify the efficacy of therapeutic treatments and vaccines currently being developed. Finally, given the unprecedented size and spread of the outbreak, as well as the extended period of replication in human hosts, specific attention is given to the 2014-2015 West African outbreak variant (Makona).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.